MediTrust Health and Sino Biopharm Sign Strategic Cooperation Agreement at CIIE 2025 to Advance Drug-Insurance Integration New Model

Core Insights - Sino Biopharmaceutical Limited and Shanghai MediTrust Health Technology Group signed a strategic cooperation agreement to enhance access to innovative drugs and commercial insurance, aiming for drug-insurance integration [1][5] Company Overview - Sino Biopharm generates annual revenue of approximately RMB 30 billion and ranks 38th among the Top 50 Global Pharmaceutical Companies, with a pipeline of over 120 innovative drugs [3] - MediTrust Health focuses on transforming China's healthcare payment system, leveraging AI and data-driven solutions to improve the "diagnosis-treatment-payment" journey [7] Strategic Goals - The partnership aims to explore AI, data collaboration, and innovative payment solutions to set new benchmarks for industry coordination [4] - The collaboration aligns with the "Healthy China 2030" strategy, enhancing drug accessibility and creating a win-win ecosystem for the pharmaceutical and insurance sectors [5] Financial Impact - MediTrust Health has serviced approximately 393 million commercial health insurance policies, achieving cumulative savings of RMB 6.7 billion in out-of-pocket costs for patients [7]